Skip to content
S1413Senate2021-2022 SessionSame asA2383

Cap Insulin Out-of-Pocket Costs

Official title

“Relates to capping cost sharing for insulin”

Sponsor Gustavo RiveraSD-33+12 co-sponsorsAffects Finance
Status
In Assembly Committee
Insurance
Impact
7/10
Significant
Passage
0%

Bill progress

Step 5 of 7

In Assembly · Insurance

What's happening

This bill lowers the out-of-pocket cap for prescription insulin to $30 per 30-day supply for insured New Yorkers.

Why it matters

  1. Significantly reduces the financial burden. for insured New Yorkers who rely on insulin, making it more affordable for individuals with diabetes to manage their health and potentially preventing dangerous cost-cutting measures like rationing insulin.

  2. Applies the $30 cap regardless of the type or amount of insulin needed. , ensuring that patients with more complex needs or higher doses are not penalized with higher costs.

  3. Mandates the cap across multiple types of insurance policies. (individual, group, and nonprofit health plans), expanding the benefit to a broad range of insured people rather than just select plans.

  4. Overrides typical cost-sharing mechanisms. (like deductibles, copays, and coinsurance) for insulin, meaning insurers cannot require higher payments from patients even if those cost-sharing features exist in the policy.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Cap Insulin Out-of-Pocket Costs

Plain English, a few words. Used as the page title.

Sponsors

History

  1. Referred to insurance
  2. Delivered to assembly
  3. Passed senateVote 60–1
  4. Advanced to third reading
  5. 2nd report cal.
  6. 1st report cal.486
  7. Referred to insurance
  8. Returned to senate
  9. Died in assembly
  10. Referred to insurance
  11. Delivered to assembly
  12. Passed senateVote 62–1
Show 4 earlier actions
  1. Advanced to third reading
  2. 2nd report cal.
  3. 1st report cal.477
  4. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A2383Assembly

Cap Insulin Copays at $30

In Assembly Committee · Insurance · Sponsor Yuh-Line Niou

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

1413

2021-2022 Regular Sessions

IN SENATE

January 12, 2021

Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law, in relation to capping cost sharing for insulin

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subparagraph (B) of paragraph 15-a of subsection (i) of section 3216 of the insurance law, as amended by section 1 of part DDD of chapter 56 of the laws of 2020, is amended to read as follows:

(B) Such coverage may be subject to annual deductibles and coinsurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy; provided however, the total amount that a covered person is required to pay out of pocket for covered prescription insulin drugs shall be capped at an amount not to exceed [one hundred] thirty dollars per thirty-day supply, regardless of the amount or type of insulin needed to fill such covered person's prescription and regardless of the insured's deductible, copayment, coinsurance or any other cost sharing requirement.

§ 2. Subparagraph (B) of paragraph 7 of subsection (k) of section 3221 of the insurance law, as amended by section 2 of part DDD of chapter 56 of the laws of 2020, is amended to read as follows:

(B) Such coverage may be subject to annual deductibles and coinsurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy; provided however, the total amount that a covered person is required to pay out of pocket for covered prescription insulin drugs shall be capped at an amount not to exceed [one hundred] thirty dollars per thirty-day supply, regardless of the amount or type of insulin needed to fill such covered person's prescription and regardless of the insured's deductible, copayment, coinsurance or any other cost sharing requirement.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD04974-01-1

S. 1413 2

§ 3. Paragraph 2 of subsection (u) of section 4303 of the insurance law, as amended by section 3 of part DDD of chapter 56 of the laws of 2020, is amended to read as follows:

(2) Such coverage may be subject to annual deductibles and coinsurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy; provided however, the total amount that a covered person is required to pay out of pocket for covered prescription insulin drugs shall be capped at an amount not to exceed [one hundred] thirty dollars per thirty-day supply, regardless of the amount or type of insulin needed to fill such covered person's prescription and regardless of the insured's deductible, copayment, coinsurance or any other cost sharing requirement.

§ 4. This act shall take effect immediately and shall apply to any policy or contract issued or renewed on or after January 1, 2022.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law, in relation to capping cost sharing for insulin

Purpose

To reduce the cap on cost sharing for insulin from the current $100 per insulin per month to $30 per insulin per month.

Summary of provisions

Sections 1 through 3 of the bill amend various sections of insurance law which were amended as part DDD of Chapter 56 of the laws of 2020, the adopted budget, to change the $100 limit on cost sharing for insulin to a $30 limit on cost sharing for insulin.

Section 4 of the bill provides for an effective date.

Justification

2.1 million New Yorkers have diabetes and 30% of type two diabetics are insulin dependent. There are 20,000 hospitalizations in NY each year with a principal diagnosis of diabetes related complications including diabetic ketoacidosis.

Type 1 and some Type 2 diabetics depend upon insulin for their very survival. In 2016, the average person with type 1 diabetes incurred annual insulin costs of $5,705.00. While some pay less, many others pay many times this amount. When patients can't afford insulin, which can cost thousands of dollars even for those who are insured, they resort to rationing the little medication they can afford. In fact, one study found that one in four people with type 1 diabetics admitted to not taking their insulin as prescribed, or rationing, due to the cost. Complications from rationing insulin are extreme leading to amputations, Diabetic KETOACIDOSIS, also referred to as DKA, and even death.

As part of the adopted 2020-21 state budget a cap on cost sharing was adopted (Part DOD, Chapter 56 of 2020). However, unlike the legislation which passed the Senate in 2019 (S 6497A) capping the cost of all insu- lins a person needs per month at $100, the budget language capped cost sharing per prescription. Given many diabetics rely on two or three different types of insulin they may still have cost sharing of $300 per month. This legislation changes the $100 cap to a $30 cap on each insu- lin per month more in line with our original legislation.

A $30 cap on insulin is also in line with the caps other states are pursuing and adopting to address access to affordable insulin. For exam- ple, Utah recently adopted a $30 copay and states such as New Mexico, Virginia, California, and Connecticut are all in various stages of pass- ing and adopting copays that range from $25 to $50 per insulin. While New York's new law capping insulin is an important first step, we must truly make access to insulin affordable and reduce the copay to $30 per insulin per month.

Prior legislative history

2019-2020: S8255/A10821 Niou

Fiscal implications

No cost to the state.

Effective date

Immediately and shall apply to any policy or contract written or renewed on or after January 1, 2022.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.